As Vice President of Portfolio Management, Rachel manages the in-house drug discovery and development portfolio at BenevolentAI and has oversight of the project management team. This requires a deep understanding across all stages of target Identification, discovery and development, shaping the strategic direction of drug discovery project management and driving continuous improvement. At BenevolentAI, Rachel’s mission is to operationalise science through excellence in portfolio and project management and is driven by improving or eliminating burdensome non-scientific processes in such programmes.
Rachel has a PhD in analytical chemistry and 18 years of experience in scientific and business operations roles in the pharmaceutical industry and life sciences sectors. In a previous role at MSD (formerly Schering-Plough), she supported building a new translational medicine research laboratory in Biopolis Singapore and led a team of scientists to develop and execute LC-MS based assays for target validation and biomarker discovery to advance early drug discovery across multiple therapeutic areas.